Potential Role of Home-Use HIV Test Kits Bernard M. Branson, M.D. A ssociate Director for Laboratory Diagnostics Division of HIV/AIDS Prevention.

Slides:



Advertisements
Similar presentations
Rapid HIV Testing and Its Role in Advancing HIV Prevention: 2004 Update Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers.
Advertisements

Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.
Rapid HIV Testing: 2005 Update Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Division of HIV/AIDS Prevention.
Sexually Transmitted Disease Surveillance 2013 Division of STD Prevention.
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
HIV Testing in Health-Care Settings
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
CDC HIV Diagnostics Conference December 5-7, 2007 Sensitivity of OraQuick and Early Generation Enzyme Immunoassay (EIA) within a Pooled HIV Nucleic Acid.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
1 MMWR (60), Of all with HIV infection, ~850,000 individuals do not have suppressed HIV RNA (72%) 100 % 75% 50% 25% 80 % 77 % 66 % 77 % 89 % Gaps.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
Rapid HIV Tests Norman Moore, Ph.D. Director of Medical Affairs.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Increasing Our Reach through Rapid HIV Testing Bernard M. Branson, M.D. Chief, Lab Determinants and Diagnostics Section Centers for Disease Control and.
Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,
What is the risk of acquiring HIV from oral sex? Workshop Ground Rules Confidentiality Use “I” statements Pass if you want Agree to Disagree Leave PC.
HIV INTERVENTION FOR PROVIDERS (HIP) Principal Investigators:  Carol Dawson Rose, RN, Ph.D. and Grant Colfax, MD. Co-Investigators:  Cynthia Gomez, Ph.D.,
The HIV/AIDS Epidemic © 2005 John B. Pryor Illinois State University.
Over The Counter HIV Testing A Technology Whose Time has Come Freya Spielberg, MD MPH
1 Risks and Benefits of Home-Use HIV Test Kits Richard Forshee, Ph.D. U.S. Food and Drug Administration Center for Biologics Evaluation and Research Office.
HIV Testing in Health- Care Settings Revised Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in Health-Care Settings U.S. Centers.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
Preventing HIV/AIDS There is no way to tell just by looking whether a person is infected with HIV. Because people are unaware that they are HIV-positive,
Florida Department of Health HIV/AIDS & Hepatitis Section Annual data trends as of 12/31/2012 Living (Prevalence) data as of 05/16/2012 Epidemiology of.
Florida Department of Health HIV/AIDS Section Division of Disease Control and Health Protection Annual data trends as of 12/31/2013 Living (Prevalence)
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
HIV Screening and Women’s Health Health Care Education & Training, Inc. Originally developed by: Section 5: Test Options.
HIV Infection Among Those with an Injection Drug Use*- Associated Risk, Florida, 2012 Florida Department of Health HIV/AIDS and Hepatitis Section Division.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV/AIDS, Viral Hepatitis,
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics
Performance of rapid HIV tests used singly and in combination: Moving toward a point of care diagnosis. Kevin Delaney, MPH HIV Diagnostics: New Developments.
Centers for Disease Control and Prevention CDC Half-Year of Diagnosis** Number of Cases **Adjusted for reporting delay AIDS Cases in Racial/Ethnic Minorities*
Universal HIV Testing Closing the Gap Peter A. Leone, MD Associate Professor of Medicine University of North Carolina Medical Director, NC HIV/STD Prevention.
Limitations of HIV Antibody Testing in a Population with High Incidence of HIV Infection Joanne Stekler 1,2, Paul D. Swenson 1,2, Robert W. Coombs 1, Joan.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
Wisconsin Department of Health Services HIV/AIDS Surveillance Annual Review New diagnoses, prevalent cases, and deaths through December 31, 2013 April.
THE BODY PRO The HIV Resource for Health Care Professionals Copyright © 2009 The HealthCentral Network, Inc. All rights reserved. This activity is jointly.
RTI International is a trade name of Research Triangle Institute Untreated chlamydial infection among adolescents and young adults in Baltimore,
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Division of HIV/AIDS Prevention National Center for HIV/AIDS, Viral Hepatitis, STD,
Poverty and HIV Infection: NHBS National* and San Diego Findings Vanessa Miguelino-Keasling, MPH National HIV Behavioral Surveillance System.
Context and Association of Meth Use and Sexual Risk Behavior David W. Purcell, JD, PhD Prevention Research Branch Division of HIV/AIDS Prevention, NCHHSTP,
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
Faiza Ali MD, Ericka Hayes MD, Gaurav Kaushik MPH, Nicole Carr RN, Katie Plax MD Washington University School Of Medicine Department of Pediatrics.
1 PHSKC 4/01 Epidemiology of HIV/AIDS Seattle-King County, WA HIV/AIDS Epidemiology Program Public Health - Seattle & King Co. (206) On the web.
Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.
SSuN: MSM prevalence monitoring and HIV Testing in STD Clinics Kristen Mahle & Lori Newman SSuN Call #3 Oct 30, 2008.
HIV Infection Among Those with an Injection Drug Use*-Associated Risk, Florida, 2014 Florida Department of Health HIV/AIDS Section Division of Disease.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
HIV Care Continuum Persons Living With HIV, Georgia, 2012.
Hepatitis C: The Silent Epidemic Wednesday, October 21, 2015 John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,
Sexually Transmitted Disease (STD) Surveillance Report, 2008 Minnesota Department of Health STD Surveillance System Minnesota Department of Health STD.
1 HIV/STD in Texas Ann Robbins Texas Department of State Health Services June 2009.
Correlates of HIV incidence among black men who have sex with men in 6 U.S. cities (HPTN 061) B. KOBLIN, K. MAYER, S. ESHLEMAN, L. WANG, S. SHOPTAW, C.
HIV Testing in Medical Settings Mark Thrun, MD Denver Public Health
Sexually Transmitted Disease Surveillance 2013 Division of STD Prevention.
HIV Testing in Acute Care Settings Rich Rothman, MD, PhD, FACEP CDC, DHHS, OraSure Technologies, Abbott  Historical.
Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV, STD, and TB Prevention.
Housing Status and HIV Risk Behaviors Among Homeless and Housed Persons with HIV in the United States The findings and conclusions in this presentation.
CT and GC Screening: What about the guys?! Gale R Burstein, MD, MPH, FAAP, FSAHM Erie County Department of Health SUNY at Buffalo School of Medicine Buffalo,
Universal Opt-Out Screening for HIV in Health Care Settings, Cost Effectiveness in Action Douglas K. Owens, MD, MS VA Palo Alto Health Care System and.
Katarina Grande, HIV Surveillance Coordinator Casey Schumann, HIV Epidemiologist Wisconsin Department of Health Services Statewide Action Planning Group.
CONCLUSIONS New Jersey’s Emergency Department HIV testing sites report higher seroprevalence than non-ED testing sites. Since University Hospital began.
HIV Screening for Patients years: A Guide for TB Clinic Providers Best Practices in TB Control - August 28, Philip J. Peters, MD Medical Officer.
Monitoring HIV risk behaviors among heterosexual couples: Challenges and lessons learned Amy Lansky, Tricia Martin, Melissa Cribbin Behavioral Surveillance.
Amy Lansky, Elizabeth DiNenno Behavioral Surveillance Team
1985: First HIV-1 ELISA Approved by FDA
MSM Attending STD Clinics HIV Testing More Frequently: Implications for HIV Prevention and Surveillance D Helms1, H Weinstock1, K Mahle1, A Shahkolahi1,2,
Presentation transcript:

Potential Role of Home-Use HIV Test Kits Bernard M. Branson, M.D. A ssociate Director for Laboratory Diagnostics Division of HIV/AIDS Prevention

95% Confidence Interval Number HIV infected 1,106,400 (1,056,400 – 1,156,400) Number unaware of their HIV infection 232,700 (21%) (221,200 – 244,200) Estimated new infections 56,300 (48,200 – 64,500) annually Persons with HIV and Awareness of HIV Status, United States Campsmith M et al, MMWR October 2008 Hall I, et al JAMA August 2008

Estimated Rates of new HIV Infections by Race/ethnicity 50 U.S. States & DC, 2006 Total Male: 34.3 per 100,000 Total female: 11.9 per 100,000

Estimated Number of New HIV Infections by Transmission Category Extended Back-Calculation Model, 50 U.S. States & DC, MSM Heterosexual IDU

Uni-Gold Recombigen Multispot HIV-1/HIV-2 Reveal G3 OraQuick Advance Clearview Complete HIV 1/2 Clearview HIV 1/2 Stat Pak

FDA-approved Rapid HIV Tests Sensitivity (95% C.I.) Specificity (95% C.I.) Oral fluid OraQuick Advance Whole blood OraQuick Advance UniGold Recombigen Clearview Stat-Pak Clearview Complete 99.3 ( ) 99.6 ( ) 100 (99.5 – 100) 99.7 (98.9 – 100) 99.7 (98.9 – 100) 99.8 ( ) 100 (99.7 – 100) 99.7 (99.0 – 100) 99.9 (98.6 – 100) Serum/plasma Reveal G3 Multispot 99.8 (99.2 – 100) 100 (99.9 – 100) 99.1 (98.8 – 99.4) 99.9 (99.8 – 100)

Postmarketing Surveillance: No. of Tests HIV Seropositivity Median % (range) Estimated Specificity Median % (range) PPV Median % (range) RT whole blood135, ( )99.98 ( )99.2 ( ) RT oral fluid26, (0-4.0)99.89 ( )90.0 ( ) Project-specific median (range) for confirmed HIV seropositivity, specificity and positive predictive value of OraQuick (347 testing sites, 14 project areas) Wesolowski et al, AIDS 2006

Developments Since March 2006 BPAC

Rapid Test Utilization by Health Departments In 2008:  2,093,339 rapid HIV tests (estimated)  52% of all HIV tests conducted  87% of all HIV tests in community-based sites Clients increasingly familiar with rapid HIV tests

Counseling with Testing 2006 CDC Recommendations for health-care:  Provide written or oral pre-test information; emphasis on post-test counseling for persons who test HIV+ USPSTF 2008 Review:  Moderate to high-intensity behavioral counseling is effective in reducing STI incidence in high-risk populations.  Little evidence suggests that single-session interventions or interventions lasting less than 30 minutes were effective in reducing STIs. - CDC, MMWR Lin et al, Annals Internal Medicine 2008

Potential Role of Home-Use Tests 1. Persons who might not otherwise be tested

Decrease in Anonymous vs Confidential HIV Tests, Florida, % 1.2% - Florida Dept of Health, HIV Counseling and Testing Annual Report, 2008

Men with Male Sex Partner in Past Year: Disclosure to Health-Care Provider DisclosedDid Not DiscloseOdds Ratio Total277 (61%)175 (39%) Age <28111 (52%)101 (48%)1 (Reference) ≥ (69%) 74 (31%)2.04 Education College grad 161 (74%) 58 (27%)6.94 Some college 67 (56%) 53 (44%)3.16 HS graduate 39 (50%) 2.50 Less than HS 10 (29%) 25 (71%)1 (Reference) - Bernstein et al, National HIV Behavioral Surveillance, NYC, Arch Int Med 2008

Men with Male Sex Partner in Past Year: Disclosure to Health-Care Provider DisclosedDid Not DiscloseOdds Ratio Race/ethnicity White134 (81%)31 (19%)1 (Reference) Black38 (40%)56 (60%)0.16 Hispanic65 (52%) 61 (48%)0.25 Sexual Preference Heterosexual 0 5 (100%) Homosexual274 (78%) 77 (22%) Bisexual 0 86 (100%) - Bernstein et al, National HIV Behavioral Surveillance, NYC, Arch Int Med 2008

Potential Role of Home-Use Tests 1. Persons who might not otherwise be tested 2. More frequent testing for high-risk persons CDC Recommendation: Persons with known risk factors for HIV infection should be tested at least annually.

HIV Testing Among IDU HIV Testing Survey,  90% previously tested 5 cities, 1998 – 2002 *  93% previously tested  69% tested within previous year - Kellerman et el, JAIDS Heimer et al, AJPH 2007 *Chicago IL, Hartford CT, New Haven CT, Oakland CA, Springfield MA

HIV Testing Among MSM Young MSM study,  88% previously tested, 54% in previous year National HIV Behavioral Surveillance :  92% previously tested, 77% in previous year 57,131 MSM visits to STD clinics, Denver, DC, San Francisco, Seattle  94% previously tested  Median inter-test interval 243 days - MacKellar et al, Sex Transm Diseases CDC, MMWR Surveillance Summaries Helms et al, JAIDS 2009

Total Tested HIV Prevalence No. % Unrecognized HIV Infection No. % Age Group (yrs) (14)45(79) (17)37(70) (29)83(49) (37)41(30) ≥ (31)11(34) Race/Ethnicity White616127(21)23(18) Black444206(46)139(67) Hispanic466 80(17)38(48) Multiracial 86 16(19) 8(50) Other139 18(13) 9(50) Total1,767450(25)217(48) HIV Prevalence and Proportion of Unrecognized HIV Infection Among 1,767 MSM, by Age Group and Race/Ethnicity NHBS, Baltimore, LA, Miami, NYC, San Francisco MMWR June 24, 2005

Total Tested HIV Prevalence No. % Unrecognized HIV Infection No. % Age Group (yrs) (14)45(79) (17)37(70) (29)83(49) (37)41(30) ≥ (31)11(34) HIV Prevalence and Proportion of Unrecognized HIV Infection Among 1,767 MSM, by Age Group and Race/Ethnicity NHBS, Baltimore, LA, Miami, NYC, San Francisco MMWR June 24, 2005  Of those with unrecognized HIV infection: - 84% previously tested - 42% tested in the preceding year Unaware ≠ Untested

Parameters Determining Potential Utility of Home-Use Tests for Public Health Characteristics/demographics of likely users Ability of users to obtain accurate results Users understanding of instructional materials, including limitations (e.g., window period before antibody development; importance of confirmation) Mechanisms for obtaining follow-up testing and care Benefits and adverse consequences from receiving a positive test result Cost of the test

Likely Users Are Difficult to Predict HIV Testing Survey, :  19% would choose a home kit for their next HIV test Home Collection HIV Test Kit Approved July 1996 HIV Testing Survey, :  54% had heard of home test kits  1% had used home test kit

CDC Qualitative Research, focus groups:  8 with MSM, 2 with high-risk heterosexual women  Miami, New Orleans, New York City, San Francisco, Washington, DC  Participants years of age Conducted shortly after CLIA waiver but before widespread use of rapid HIV tests by health departments  First CLIA waiver approved January 31,2003  Oral fluid rapid test received CLIA waiver June 25, 2004

Focus Groups: Major Themes Might encourage some persons to get tested Testing with partner might allow unprotected sex, especially in long-term relationships Seeing it used in clinics and doctor’s office would lend credibility about accuracy More likely to use if recommended by their doctor Would not consider positive result definitive or replacement for seeing a doctor

Focus Groups: Major Themes Most reacted negatively to asking a new acquaintance to test before casual sex, but geographical differences Understanding (and concern) about window period Essential: Some means of getting access to counseling or support must be provided for persons who test positive Expect test to cost $10 to $30

Potential Role of Home-Use Tests 1. Persons who might not otherwise be tested 2. More frequent testing for high-risk persons 3. Mutual testing with sex partners

HIV Testing with Prospective Partners 2006 CDC Recommendation:  Health-care providers should encourage patients and their prospective sex partners to be tested before initiating a new sexual relationship. “Serosorting” among MSM:  Practice of preferentially choosing sex partners, or deciding not to use condoms with selected partners, based on their disclosed, concordant HIV status

“Serosorting”: Mixed Evidence Increasing practice among MSM HIV-infected MSM: decrease in proportion of unprotected sex acts with uninfected partners 1 HIV-negative MSM: unprotected intercourse with partner believed to be negative was an independent risk factor for acquiring HIV 2,3 With serosorting among MSM, decline in equilibrium HIV prevalence as frequency of HIV testing increases 4 1 Steward et al, AIDS Behav Koblin et al, AIDS Buchbinder et al JAIDS Cassels et al, AIDS 2009

Potential Role of Home-Use Tests 1. Persons who might not otherwise be tested 2. More frequent testing for high-risk persons 3. Mutual testing with new sex partners 4. Repeat testing after potential “window period”

WB positive RNA 3 rd generation EIA 2 nd generation EIA Flow-through RT 1 st generation EIA Lateral flow RT Days before Western blot positive when 50% of Specimens Reactive WB Indeterminate Window period: Current Assays with 15 Seroconverter Panels 185 specimens from 15 seroconverters Owen et al, J. Clin. Microbiol 2008 Flow-through RT Lateral flow RT

Undetected “Window Period” Infections in High-Risk Populations Rapid test negative, detectable RNA:  0.3% of 14,005 frequently tested MSM in Seattle STD clinic; represent 20% of all HIV infections detected  0.08% of 21,222 STD clinic patients in New York City; represent 9% of all HIV infections detected - Stekler et al, Clin Infect Dis Shepard et al, MMWR in press

Potential Role of Home-Use Tests 1. Persons who might not otherwise be tested 2. More frequent testing for high-risk persons 3. Mutual testing with new sex partners 4. Repeat testing after potential “window period” 5. Dispense via pharmacists with counseling 6. Provide to HIV-infected persons for use when notifying partners (analogy: expedited partner therapy for chlamydia)

Additional Considerations 2-test combination would be preferable to increase predictive value of positive test result Engagement in ongoing care and prevention is ultimate goal for persons who test positive